Clinical trial
A Randomized Double-Blind Trial of Abatacept Extended Dosing Versus Abatacept Short-term Dosing for Graft Versus Host Disease Prophylaxis: "ABA3"
NCT04380740 is registered in ClinicalTrials.gov with Boston Children's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Double-Blind Trial of Abatacept Extended Dosing Versus Abatacept Short-term Dosing for Graft Versus Host Disease Prophylaxis: "ABA3"
- Lead sponsor
- Boston Children's Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- March 30, 2022
- Completion date
- June 30, 2028
- Enrollment
- 160 (estimated)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.